Despite its increasing incidence in men, the only widely-available test for prostate cancer, PSA, is limited not only by its poor sensitivity and specificity, but also by the uncertainty relating to the natural history and the management of the disease [2,3]. Here, KLK3 is linked to prostate carcinoma.